MedTrace Logo

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

NCT00492440 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-10-18

No results posted yet for this study

Summary

RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally advanced or metastatic kidney cancer.

Conditions

Interventions

BIOLOGICAL

recombinant interleukin-7

GENETIC

gene expression analysis

GENETIC

polymerase chain reaction

GENETIC

protein expression analysis

OTHER

flow cytometry

OTHER

immunoenzyme technique

OTHER

immunologic technique

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Sponsors & Collaborators

  • Cytheris, Inc.

    collaborator INDUSTRY

  • Cytheris SA

    lead INDUSTRY

Principal Investigators

  • Steven A. Rosenberg, MD, PhD · NCI - Surgery Branch

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-07-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00492440 on ClinicalTrials.gov